Treatment with Aricept (donepezil) significantly improved memory, thinking and global function in patients with vascular dementia compared with placebo, according to an article published in this month’s issue of the peer-reviewed journal Neurology.
Related Results
Health: A ricept isn’t a cure, but it has made me a …
MODE OF ACTION
Reversible Cholinesterase Inhibitor
Preferential inhibition of acetyicholinesterase in the central nervous system.
Increases concentration of acetylcholine by preventing its hydrolysis by cholinesterase.
Result is im…
Eisai Co., Ltd. (Tokyo, Japan) and its United States subsidiary Eisai Inc. (Woodcliff Lake, NJ) announced that the United States District Court for the District of New Jersey has ruled in Eisai’s favor with respect to Eisai’s motion for a preliminary injunction in its patent infringement lawsuit agains…
Tokyo, Dec 21, 2005 - (JCN) - Eisai has announced that its US subsidiary Eisai Medical Research resubmitted a supplemental new drug application (sNDA) for Aricept, the company’s proprietary agent for treating severe Alzheimer’s disease, to the US Food and Drug Administration (FDA) as of December 16.
…
Eisai has taken on the U.S. distribution responsibilities for its Aricept (donepezil hydrochloride tablets) for treatment of mild to moderate Alzheimer’s disease. Formerly the domain of Pfizer, Eisai’s co-marketing partner, the U.S. distribution has been acquired by Eisai in an effort to “achieve independence and growth in the manufacturing, distribution and promotion of its own products …,” according to a company announcement.
The company also stated that it will continue to fost…
Eleven of 648 patients died while taking donepezil (Aricept) in a trial of the drug for the treatment of vascular dementia, according to preliminary study results announced by Eisai Co. Ltd., the drug’s maker. None of the 326 patients taking placebo during the 24-week trial died.
The multicenter, randomized, double-blind study was conducte…
DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c37632) has announced the addition of the Espicom Business Intelligence Ltd report: Eisai Pharmaceutical Company Intelligence Report to their offering.
Pharmaceut…
